A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals ...

Background The Six-minute walk (6MW) and Timed-Up-and-Go (TUG) are short walk tests commonly used to evaluate functional recovery after total knee arthroplasty (TKA). However, little is known ...

Few treatments are available for people with Duchenne muscular dystrophy. The FDA's accelerated approval program can help ...

People can struggle to regain balance, stability and gait coordination for daily life activities and even proper ambulation." ...

Good afternoon, and welcome to the Sarepta Therapeutics first quarter 2024 earnings call. At this time, all participants are ...

NDAQ:SRPT) Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Givinostat (Duvyzat) slowed physical decline as measured by ...

The NDA resubmission for Translarna will be based on the placebo-controlled results from Study 41 and data from the STRIDE ...

The patented technology focuses on a design feature that allows healthcare providers to switch seamlessly between stationary operation and “transport” or “ambulation” mode, enabling unprecedented ...

Maximizing functional mobility is a key goal of rehabilitation after total knee arthroplasty (TKA) surgery. The Timed-Up-and-Go (TUG) and Six-minute walk (6MW) tests are commonly used to evaluate ...

Sarepta Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.37, expectations were $-0.11. Sarepta Therapeutics ...

Q1 2024 Sarepta Therapeutics Inc Earnings Call ...